← Back to Search

Topical Agent

VTAMA (tapinarof) cream, 1% for Psoriasis

Phase 4
Waitlist Available
Research Sponsored by Dermavant Sciences, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants with clinical diagnosis of plaque psoriasis, including lesion(s) in the head and neck region and stable disease in the head and neck region for at least 3 months prior to the study
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to week 12
Awards & highlights

Study Summary

This trial tests a new cream for adults with psoriasis on their head and neck, to see how safe and effective it is.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You have been diagnosed with plaque psoriasis, including lesions on your head and neck, and your condition has been stable for at least 3 months before the study.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to week 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to week 12 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of participants who achieve a target lesion Physician Global Assessment (PGA) score in the head and neck region of Clear (0) or Almost Clear (1) with a ≥ 2-grade improvement from Baseline to Week 12
Secondary outcome measures
Time to achieve a target lesion PGA score of Clear (0) or Almost Clear (1) with a ≥ 2-grade improvement

Trial Design

1Treatment groups
Experimental Treatment
Group I: VTAMA (tapinarof) cream, 1%Experimental Treatment1 Intervention
VTAMA (tapinarof) cream, 1% applied topically once daily
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
VTAMA (tapinarof) cream, 1%
2023
Completed Phase 4
~40

Find a Location

Who is running the clinical trial?

Dermavant Sciences, Inc.Lead Sponsor
5 Previous Clinical Trials
1,171 Total Patients Enrolled
3 Trials studying Psoriasis
174 Patients Enrolled for Psoriasis
Philip Brown, MD, JDStudy DirectorChief Medical Officer, Dermavant Sciences, Inc.

Media Library

VTAMA (tapinarof) cream, 1% (Topical Agent) Clinical Trial Eligibility Overview. Trial Name: NCT05789576 — Phase 4
Psoriasis Research Study Groups: VTAMA (tapinarof) cream, 1%
Psoriasis Clinical Trial 2023: VTAMA (tapinarof) cream, 1% Highlights & Side Effects. Trial Name: NCT05789576 — Phase 4
VTAMA (tapinarof) cream, 1% (Topical Agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05789576 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many sites are actively conducting this trial?

"The existing 10 sites participating in this trial are located across the country, including Chicago, Rockville and Auburn Hills. Prospective participants should select a location nearby to reduce travel obligations when enrolling."

Answered by AI

Has recruitment for this trial commenced?

"According to clinicaltrials.gov, the given medical trial is actively recruiting participants - it was initially posted on March 13th 2023 and last updated April 25th of the same year."

Answered by AI

What is the aggregate number of individuals partaking in this investigation?

"Affirmative, according to the information posted on clinicaltrials.gov, this research is actively seeking patient involvement. The trial was initially published on March 13th 2023 and most recently updated April 25th of the same year. 30 individuals need to be recruited from 10 sites for successful completion."

Answered by AI

Has the United States Food and Drug Administration sanctioned VTAMA (tapinarof) cream, 1%?

"There is evidence to support the safety and efficacy of tapinarof cream, which has been approved for use in a Phase 4 trial. Thus, our team at Power ranked it as 3 on our scale from 1-3."

Answered by AI
~15 spots leftby Mar 2025